HCM
NVAX icon

Highbridge Capital Management’s Novavax NVAX Stock Holding History

Highbridge Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-865
Closed -$89K – 1632
2016
Q1 		$89K Buy
865
+150
+21% +$16.1K ﹤0.01% 1407
2015
Q4 		$120K Buy
+715
New +$110K ﹤0.01% 1410
2014
Q2 		– Sell
-610
Closed -$55K – 1228
2014
Q1 		$55K Buy
+610
New +$68.1K ﹤0.01% 1003

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's NVAX Position: Q3 2015 in Review

Highbridge Capital Management sold out of Novavax (NVAX) in Q3 2015, closing a stake of 10,446 shares — an estimated $2.33M sold.

Highbridge Capital Management first reported a position in NVAX in Q1 2014 and held it in 4 quarters. The position peaked at $2.33M in Q2 2015. 190 funds tracked by Wall St. Rank hold NVAX as of Q3 2015.

  • Highbridge Capital Management reported no remaining Novavax position as of Q3 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 10,446 Novavax shares in Q3 2015, an estimated $2.33M.
  • Highbridge Capital Management first reported a position in Novavax in Q1 2014 and held it in 4 quarters.
  • Highbridge Capital Management's Novavax position peaked at $2.33M in Q2 2015.
  • 190 funds tracked by Wall St. Rank held Novavax as of Q3 2015.

Based on Highbridge Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.